Levacin

Quick links to important sections

Levacin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levacin

Quick Facts

Property Description
Active ingredient Levodopa and Carbidopa
Form Tablet, Capsule, Suspension (for enteral use)
Pharmacological class Dopaminergic Antiparkinsonism Agent
Common use Symptomatic management of Parkinson's disease
Origin Synthetic combination drug

What Type of Medicine is Levacin and What is its Purpose?

Levacin is classified as a prescription-only, combination central nervous system (CNS) agent belonging to the pharmacological group of Dopaminergic Antiparkinsonism Agents. Its primary purpose is the symptomatic management of Parkinson's disease and related conditions. The medicine is clinically recognized as an effective symptomatic treatment for the disease, directly addressing the fundamental deficiency of the neurotransmitter dopamine observed in these conditions.

The drug is a crucial tool in modern therapy because it directly supports the brain's ability to regulate movement. By increasing the amount of dopamine available in the brain, Levacin generally helps to relieve the core motor symptoms, such as stiffness and tremor, associated with the condition. This combination is established as a significant component in global healthcare for managing these symptoms.


The Composition: Levodopa, Carbidopa, and Origin

Levacin contains two synthetic active ingredients: Levodopa and Carbidopa. Levodopa is a dopamine precursor—a prodrug that is converted into dopamine after crossing the blood-brain barrier. Carbidopa is a peripheral dopa decarboxylase inhibitor that does not cross the barrier, but prevents the premature breakdown of levodopa outside the central nervous system.

This combination is available in several dosage forms, including the most common oral tablet, as well as extended-release capsules and suspensions for enteral administration. The strategic rationale for the dual composition is that Carbidopa protects Levodopa in the periphery, thereby maximizing the amount of the therapeutic precursor delivered to the central nervous system to restore chemical balance.

Regulatory References

  1. WHO Essential Medicines List entry for Levodopa + Carbidopa

What side effects are possible with Levacin?

Possible Side Effects and Safety Information

The safety profile of Levacin (Levodopa/Carbidopa) is primarily defined by effects on the Central Nervous System and is documented within official regulatory classifications.

Motor complications are a key characteristic of the drug's profile, including dyskinesia (involuntary movements) and motor fluctuations (e.g., 'on-off' phenomena). Regulatory documents note that dyskinesia may appear at lower dosages and sooner in combination therapy than with levodopa alone, while blepharospasm may be an early sign of excess dosage.

Officially documented psychiatric effects are common and include hallucinations, abnormal dreams, confusion, and the reported emergence of Impulse Control Disorders. Serious adverse reactions include severe depression with suicidal tendencies and psychotic episodes.

Systemic effects often involve the Gastrointestinal system, with nausea being classified as a very common event. Vascular effects include orthostatic hypotension and syncope.

A syndrome resembling Neuroleptic Malignant Syndrome (NMS), a potentially serious condition, has been reported in association with the abrupt withdrawal or rapid dose reduction of this medicine. The drug is contraindicated in patients with narrow-angle glaucoma, a history of melanoma, or concurrent use of non-selective MAO inhibitors. Safety and efficacy have not been established for patients under 18 years of age.

Overdose and Emergency Response

Overdose and when to seek help

If you believe an overdose of Levacin has occurred, seek emergency medical attention or contact a Poison Help center immediately. An overdose may lead to signs and symptoms affecting the nervous system, potentially including headache, nausea, vomiting, dizziness, confusion, seizures, or tremors.

When to Seek Emergency Medical Attention

Immediate emergency medical help is required if a person has taken too much Levacin and experiences:

  • Seizures or loss of consciousness.
  • Severe difficulty breathing.
  • Any signs of a severe allergic reaction, such as swelling of the face, tongue, or throat, or hives.
  • Severe and persistent chest, back, or stomach pain.

Overdose Management

Overdose management in a medical setting may include supportive measures. If the overdose is recent, stomach evacuation (e.g., gastric lavage) may be considered by a healthcare professional. Adequate hydration is important. Hemodialysis or peritoneal dialysis may not be effective in removing Levacin from the body. Treatment focuses on managing the specific clinical signs and symptoms that appear.

Always follow the instructions of emergency medical personnel or a poison control center.

Therapeutic Uses of Levacin

What Levacin Treats: Main Uses and Benefits

Quick Facts

  • Targeted Use: Addresses a range of infections caused by certain susceptible bacteria.
  • Respiratory Support: May be prescribed for community-acquired pneumonia and flare-ups of chronic bronchitis.
  • Other Applications: Used to manage infections of the prostate, kidney, and urinary tract.
  • Specific Exposures: Utilized for post-exposure management of inhalational anthrax and the treatment of plague.

Levacin is a prescription medication utilized in therapeutic contexts to address conditions caused by specific types of susceptible bacteria. It is commonly employed to help resolve infections in several areas of the body.

The authorized therapeutic domains for Levacin include infections affecting the respiratory system, such as community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. The medication may also be indicated for managing infections of the skin and skin structures, as well as those localized in the urinary tract, including complicated urinary tract infections and acute pyelonephritis.

Additionally, Levacin serves a role in addressing chronic bacterial prostatitis. The drug is also a component of post-exposure management for inhalational anthrax and the treatment and prophylaxis of plague.

Eligibility and Restrictions for Use

Levacin (levofloxacin) is a fluoroquinolone antibiotic used to treat a variety of bacterial infections, including those affecting the lungs, urinary tract, and skin. It is typically reserved for infections where other, safer antibiotics are not suitable, due to its potential for serious side effects.


Who Can Use Levacin (Use with Caution)

Patient Group Consideration
Adults Prescribed for specific bacterial infections.
Children Generally avoided, but may be used in those geq 6 months old for severe conditions like post-exposure anthrax or plague, with caution due to risk of joint issues.
Elderly Patients Can be used, but risk of tendon problems and heart issues may be increased. Dose adjustments may be necessary due to potential kidney or liver impairment.

Who Cannot Use Levacin (Contraindications)

Levacin is contraindicated and should not be used in patients with a known allergy to levofloxacin or any other fluoroquinolone antibiotic. Additionally, it is generally avoided in those with a history of:

  • Myasthenia gravis (may worsen muscle weakness).
  • Tendon disorders, including those related to rheumatoid arthritis, due to increased risk of tendon rupture.
  • Prolongation of the QT interval (a type of irregular heartbeat) or uncorrected low potassium (hypokalemia).

Use is often avoided in pregnant or breastfeeding women due to potential risks to the fetus or infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Levacin's interaction profile requires specific administration constraints and monitoring when used alongside certain medicinal products and substance categories.


Product Class / Specific Medicine Interaction Mechanism & Regulatory Constraint
Polyvalent Cation-Containing Products (e.g., antacids with magnesium/aluminum, sucralfate, mineral supplements, dairy) The primary mechanism is chelation, a pharmacokinetic interaction that significantly reduces the oral absorption and bioavailability of Levacin. Constraint: Oral administration must be separated by at least 2 hours before and 6 hours after the administration of these products.
Medicines that Prolong the QT Interval (e.g., Class IA and III antiarrhythmics, certain antipsychotics, macrolides) Pharmacodynamic additive effect on the cardiac QT interval, increasing the risk of potentially life-threatening arrhythmias like Torsades de Pointes. Constraint: Concomitant use with certain agents is contraindicated or requires extreme caution and close ECG and electrolyte monitoring.
Anticoagulants (e.g., Warfarin) Levacin has been officially documented to potentiate the anticoagulant effect of Warfarin, which may lead to an increased risk of bleeding. Constraint: Close and frequent monitoring of the International Normalized Ratio (INR) is required upon co-initiation and discontinuation of Levacin.
Theophylline Inhibition of the metabolism of theophylline, likely via the CYP1A2 enzyme pathway, can lead to increased Theophylline plasma concentrations and toxicity. Constraint: Serum Theophylline concentrations should be closely monitored, and a dose adjustment may be necessary.

Special Population Note: The risk associated with QT prolongation is heightened in elderly patients and those with underlying cardiac conditions or uncorrected hypokalemia or hypomagnesemia, as stated in official labeling.

Mechanism of Action

Levofloxacin, a fluoroquinolone antimicrobial, functions as a bactericidal inhibitor of essential bacterial DNA replication and transcription. Its primary biological targets are the bacterial enzymes DNA gyrase (a type II topoisomerase) and DNA topoisomerase IV.

Levofloxacin interacts by intercalating into the DNA-enzyme complex, stabilizing the covalent bond between the enzyme and the cleaved DNA strand. This interaction prevents the ligation of the broken DNA strands by the enzyme, thereby blocking the DNA's essential supercoiling, unwinding, and separation functions.

The molecular and intracellular consequence is the accumulation of lethal double-strand DNA breaks within the bacterial cell. This downstream cascade triggers the SOS response and leads to irreversible cell cycle arrest and programmed cell death. The system-level physiological consequence is a reduction in the population of susceptible bacteria.

Dosage and Administration Information

How to Use Levacin (Levofloxacin) — Administration Guidelines

This section outlines the administration instructions for Levacin (Levofloxacin), focusing strictly on procedural rules for its correct use.

Levacin is administered via the oral route (as tablets or solution) or through intravenous (IV) infusion.

Dosing and Administration Constraints

Instruction Parameter
Standard Frequency Doses are typically taken once every 24 hours (once daily). Some regimens, such as the 500 mg dose for certain severe infections, may be administered twice daily.
Timing with Food (Oral) Levacin tablets can be taken with or without food.
Interaction Window Oral Levacin must be taken at least two hours before or two hours after supplements containing magnesium, aluminum, iron, or zinc to ensure proper absorption.
IV Infusion Rate Intravenous administration must be performed via slow infusion, not by rapid injection. The infusion duration is specified to be 60 minutes for the 500 mg dose and 90 minutes for the 750 mg dose.
Renal Adjustment Dosage adjustment is required for patients with reduced kidney function (creatinine clearance less than 50 mL/min). The dose and/or frequency must be reduced according to a specific schedule outlined in the prescribing information.

Required Preparatory Steps

Ready-to-use IV solutions are available. If using concentrated single-use vials, the product must be diluted to a final concentration of 5 mg/mL before infusion. The full course of therapy must be completed as prescribed, and the patient must not double a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Efficacy and Clinical Data

Research evaluated whether the drug had findings related to minor pain. These studies often involved a single, defined dose over a short duration.

Key studies examined whether the combined formulation addressed the duration and severity of cold symptoms. The primary endpoints included symptom scores (e.g., nasal congestion, sore throat) and time to symptom resolution.

The primary evidence included a recent meta-analysis which reported findings related to headache frequency. Researchers in this analysis aggregated data from several randomized, controlled trials (RCTs) investigating the drug's use for tension-type headaches.


Safety Profile and Study Limitations

The anti-inflammatory properties of Compound B, as studied in trials, were compared to older remedies. This comparison was typically based on changes in inflammation biomarkers or patient-reported function scores.

One study also investigated the drug's use at the first sign of migraines and its connection to onset. This trial design differed from standard research by focusing on early intervention rather than established symptom treatment.

The formulation was evaluated for a rapid onset of pain relief, a finding which was reported in patient-reported outcomes (PROs). Adverse event rates reported across all trials were analyzed.

Key Studies & References

  1. An integrated safety analysis of combined acetaminophen and ibuprofen

Frequently Asked Questions (FAQ)

Common questions about Levacin (FAQ)

Q: What is the standard length of treatment typically described for Levacin?

The typical duration of treatment with Levacin generally ranges from 3 to 14 days, though this depends on the specific infection being treated. For certain severe or specialized conditions, such as postexposure prophylaxis for inhalation anthrax, the regulatory guidance describes a treatment course of up to 8 weeks.

Q: Is it typical to experience stomach upset when first starting Levacin?

Regulatory documents list nausea as a common gastrointestinal side effect associated with this medication. Nausea is a form of stomach upset, and this is noted as a possibility in official product information.

Q: What are the signs of a severe or allergic reaction associated with Levacin?

Official warnings describe severe, potentially life-threatening hypersensitivity reactions, such as anaphylactic shock and angioedema, which may occur even after a single dose. These are emergency events noted in the regulatory warnings for Levacin.

Q: Is Levacin described as safe to use during pregnancy in regulatory documents?

Regulatory documents state that Levacin is generally avoided during pregnancy, as there is insufficient data, and potential risks to the fetus cannot be ruled out.

Q: Is Levacin considered safe for use during breastfeeding?

Use is generally avoided during breastfeeding because fluoroquinolones are excreted into human milk, and a risk to the nursing infant cannot be excluded according to official product information.

Q: Does the time of day I take Levacin change its overall effectiveness?

The effectiveness of Levacin is generally based on maintaining a consistent dose once every 24 hours. Official prescribing information states that Levacin tablets can be taken with or without food. Since the active ingredient typically reaches a steady level in the body within 48 hours, the specific time of day is not noted as a factor that changes overall effectiveness, provided the medication is taken as scheduled.

Q: Can Levacin be crushed or chewed, or should it be swallowed whole?

Levacin tablets are intended to be swallowed whole and taken with sufficient liquid. Crushing or chewing the standard tablet formulation is not generally advised in the official administration guidelines.

Q: What should a patient do if they notice unusual bruising while on Levacin?

Regulatory documents mention that Levacin may affect blood clotting, particularly if taken with certain other medications like Warfarin. The official guidance indicates that a healthcare provider should be contacted if unusual bleeding or bruising occurs.

Q: Does Levacin treat viral infections or only bacterial ones?

Levacin is officially classified as a fluoroquinolone antibacterial agent indicated only for the treatment of bacterial infections. According to the prescribing information, it is not effective against viral infections, such as the common cold or flu.

Q: Is Levacin considered a 'broad-spectrum' medicine?

Levacin is officially described as a synthetic antibacterial agent from the fluoroquinolone class. This classification indicates it is effective against a wide range of both Gram-positive and Gram-negative microorganisms.

Q: Is it common to take Levacin for chronic conditions?

Levacin is primarily used to treat infections, which are often acute (short-term). However, regulatory indications include certain conditions that are chronic in nature, such as chronic bacterial prostatitis.

Q: Are generic and brand-name Levacin chemically identical according to regulators?

Regulatory bodies like the FDA approve generic versions of Levacin (levofloxacin) only if they are shown to be bioequivalent. This means they contain the identical active ingredient, strength, and dosage form, and are expected to work in the same way as the brand-name drug.

Q: Is a metallic taste in the mouth a commonly reported side effect of Levacin?

Clinical trials for Levacin have reported cases of dysgeusia, which is an altered sense of taste. This side effect is officially documented, though specific descriptions like a 'metallic taste' are patient-reported variations of this alteration.

Q: Does Levacin commonly cause drowsiness or affect alertness?

Levacin has been associated with central nervous system effects, including dizziness and insomnia. Because these effects may impact a person's ability to concentrate, official warnings note that alertness can be affected.

Q: Are there any side effects of Levacin that are considered long-term risks?

Levacin, a fluoroquinolone antibiotic, is associated with disabling and potentially irreversible serious adverse reactions. These include harm to tendons (tendinitis/tendon rupture) and a condition affecting nerves called peripheral neuropathy.

Q: What common over-the-counter pain relievers interact with Levacin?

Regulatory information indicates that certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may increase the risk of central nervous system (CNS) stimulation, including the potential for seizures, when taken alongside Levacin.

Q: Are there specific foods or beverages known to change how Levacin is absorbed?

Oral Levacin absorption is significantly reduced if it is taken concurrently with products containing polyvalent cations. This includes supplements and foods containing minerals like iron, zinc, magnesium, or aluminum (such as most antacids).

Q: Is the risk of side effects higher for people taking multiple medications with Levacin?

The risk of specific serious side effects is explicitly increased when Levacin is co-administered with certain other drugs. For instance, the risk of tendon issues is higher when taking corticosteroids, and the risk of heart rhythm problems is higher when taking medicines that prolong the QT interval.

Q: How quickly does Levacin leave the system after the last dose? / What is the 'half-life' of Levacin?

The rate at which Levacin leaves the body is quantified by its elimination half-life, a pharmacokinetic term. In individuals with normal kidney function, this half-life is typically reported to be between 6 and 8 hours.

Q: Is it necessary to drink extra water when taking Levacin?

Official administration instructions note that Levacin tablets are taken with a sufficient amount of liquid. There are no regulatory instructions that specifically mandate the intake of extra water beyond this requirement.

Q: What are the official recommendations if a person accidentally takes too much Levacin?

In the event of an overdose, official regulatory documents describe the need for immediate symptomatic treatment. Monitoring of the heart's electrical activity (ECG monitoring) may be necessary due to the risk of QT prolongation (a heart rhythm issue).

Q: Can Levacin cause sensitivity to sunlight?

Phototoxicity (an adverse reaction to light) and photosensitivity have been reported with Levacin. Regulatory warnings indicate that unnecessary exposure to strong sunlight or UV light is generally avoided during treatment.

Q: Is there evidence that Levacin contributes to antibiotic resistance?

Antibiotic resistance mechanisms are documented in Levacin's official information, which reflects that this is a critical public health concern. Prescribers are cautioned to use the medication appropriately to help mitigate the development of bacterial resistance.

Q: Is Levacin used to prevent infections, or only to treat existing ones?

Levacin is approved for treating existing bacterial infections. However, it is also indicated for the prevention of specific conditions, such as postexposure prophylaxis following potential exposure to inhalation anthrax.

Q: How is Levacin typically cleared from the body?

Levacin is cleared from the body primarily by the renal route, meaning it is processed and removed by the kidneys. This route accounts for over 85% of the administered dose.

Q: Are patients required to get blood tests while taking Levacin?

Blood monitoring is specifically required when Levacin is co-administered with certain other medications, such as frequent monitoring of the International Normalized Ratio (INR) if taken with Warfarin. Monitoring may also be necessary for those with reduced kidney function.

Q: Does Levacin have any known effects on mental clarity or mood?

Levacin has been associated with central nervous system effects, including confusion, anxiety, hallucinations, and, in rare instances, suicidal thoughts and self-endangering behavior.

Q: Is Levacin a controlled substance?

No, Levacin (levofloxacin) is not classified as a controlled substance under the U.S. Controlled Substances Act.

How should Levacin be stored and disposed of?

How to Store and Dispose of Levacin (Levofloxacin)

Official regulatory guidelines dictate specific conditions for storing and disposing of Levofloxacin to maintain product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F).
Environmental Must be protected from light and stored away from excessive heat.
Prohibitions Do not freeze.
Container Keep in the original, tightly closed container.

Safety and Disposal

All Levofloxacin must be kept out of the reach of children and sight. Expired or unused medication must be disposed of in accordance with FDA guidelines and local regulations. The preferred method is using a drug take-back program. If one is unavailable, mix the medicine with an unappealing substance (like dirt or coffee grounds), place it in a sealed bag, and throw it in the trash. Drain disposal is not recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levacin found in:

A-Z Index: